{"transactions":[{"id":1658956,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":94612,"kind":"person","name":"HAMED KAMAL","position":1,"cik":"0001946366","reported_name":"HAMED KAMAL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-06T01:45:12.000Z","date":"2024-02-02","kind":"sale","planned":false,"acquired":false,"shares":28075,"price":1.37,"value":38462.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of RSUs that were granted to the Reporting Person on February 1, 2023 pursuant to a \"sell to cover\" provision included in the RSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents the weighted average sales price per share. The shares sold at prices ranging from $1.36 to $1.41 per share. Full information regarding the number of shares sold at each price shall be provided upon request to the staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder of the Issuer."}],"balance_after":788117,"source":{"system":"sec-edgar","filing":"0000950170-24-011491","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017024011491/ownership.xml","form_type":"4"}},{"id":1658955,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":94612,"kind":"person","name":"HAMED KAMAL","position":1,"cik":"0001946366","reported_name":"HAMED KAMAL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2024-02-06T01:45:12.000Z","date":"2024-02-01","kind":"grant","planned":false,"acquired":true,"shares":239731,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2025, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":816192,"source":{"system":"sec-edgar","filing":"0000950170-24-011491","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017024011491/ownership.xml","form_type":"4"}},{"id":1780164,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":94612,"kind":"person","name":"HAMED KAMAL","position":1,"cik":"0001946366","reported_name":"HAMED KAMAL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-09-15T21:47:27.000Z","date":"2023-09-13","kind":"sale","planned":false,"acquired":false,"shares":39496,"price":1.27,"value":50159.92,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The reported transaction is a sale of common stock effected to cover tax withholding obligations in connection with the vesting of (i) restricted stock units (\"RSUs\") that were granted to the Reporting Person on September 12, 2022 pursuant to a \"sell to cover\" provision included in the RSU Agreement and (ii) performance-based restricted stock units (\"PSUs\") that were granted to the Reporting Person on August 4, 2022, subject to the achievement of certain pre-established performance criteria, which the Board of Directors of the Issuer determined had been 100% met on June 12, 2023, pursuant to a \"sell to cover\" provision included in the PSU Agreement."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reflected is the weighted-average sale price for shares sold. The shares were sold in multiple transactions and the range of sale prices for the transactions reported was $1.27 to $1.295 per share. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price."}],"balance_after":576461,"source":{"system":"sec-edgar","filing":"0000950170-23-048440","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017023048440/ownership.xml","form_type":"4"}},{"id":1855943,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":94612,"kind":"person","name":"HAMED KAMAL","position":1,"cik":"0001946366","reported_name":"HAMED KAMAL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-06-14T12:30:39.000Z","date":"2023-06-12","kind":"grant","planned":false,"acquired":true,"shares":140000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On August 4, 2022, the Reporting Person was granted a target of 140,000 performance-based restricted stock units (\"RSUs\") under the Issuer's 2019 Inducement Equity Incentive Plan, as amended.  Each RSU represents the right, upon achievement of certain pre-established performance criteria, to receive one share of the Issuer's common stock, subject to vesting conditions.  On June 12, 2023, the Board of Directors of the Issuer determined that 100% of the performance-based conditions were met resulting in 140,000 RSUs earned by the Reporting Person. The RSUs vest in two equal annual installments on September 12, 2023 and September 12, 2024, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Consists of RSUs held by the Reporting Person."}],"balance_after":615957,"source":{"system":"sec-edgar","filing":"0000950170-23-027860","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000095017023027860/ownership.xml","form_type":"4"}},{"id":2033061,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":94612,"kind":"person","name":"HAMED KAMAL","position":1,"cik":"0001946366","reported_name":"HAMED KAMAL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2023-02-04T00:40:15.000Z","date":"2023-02-01","kind":"grant","acquired":true,"shares":265957,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on February 1, 2024, subject to the Reporting Person's continued service through the applicable vesting date."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 475,957 RSUs held by the Reporting Person."}],"balance_after":475957,"source":{"system":"sec-edgar","filing":"0000899243-23-003942","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924323003942/doc4.xml","form_type":"4"}},{"id":2159359,"issuer":{"id":7014,"kind":"organization","name":"Spero Therapeutics, Inc."},"owners":[{"id":94612,"kind":"person","name":"HAMED KAMAL","position":1,"cik":"0001946366","reported_name":"HAMED KAMAL","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Medical Officer"}}],"security":"Common Stock","published_at":"2022-09-15T01:49:29.000Z","date":"2022-09-12","kind":"grant","acquired":true,"shares":210000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Consists of restricted stock units (\"RSUs\"). Each RSU represents the right to receive one share of common stock upon vesting. The RSUs vest in four equal annual installments beginning on September 12, 2023, subject to the Reporting Person's continued service through the applicable vesting date."}],"balance_after":210000,"source":{"system":"sec-edgar","filing":"0000899243-22-031094","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1701108/000089924322031094/doc4.xml","form_type":"4"}}]}